EUVIMEDEUVIMED entdecken
Crossref

Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center

Mahdi Aghili, Fatemeh Jafari, Kasra Kolahdouzan, Fatemeh Biglar, Ava Yousefi, Mansoureh Nabavi, Ramin Jaberi, Ata Garajei, Alireza Abdshah, Ali Kazemian, Luca Tagliaferri

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2025.09.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Mahdi Aghili und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran…. Hauptthemen laut MEDLINE: Brachytherapy, Tongue Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: High-dose-rate interstitial brachytherapy (HDR-IBT) is commonly used for treating oral tongue squamous cell carcinoma (OTSCC). This study aims to evaluate long-term outcomes, survival predictors, chronic side effects, and failure patterns in patients receiving adjuvant HDR-IBT after surgical resection. METHODS AND MATERIALS: We analyzed records of 239 early-stage OTSCC patients treated with surgery, and adjuvant HDR-IBT at a tertiary cancer center from October 2010 to February 2024. Follow-up included assessing survival status, disease recurrence, and chronic adverse events. RESULTS: Among the patients, 142 received HDR-IBT as monotherapy, 73 as a boost to external beam radiotherapy (EBRT), and 24 as salvage therapy. The 5-year overall survival (OS) rates were 78.4%, 56.0%, and 53.5%, while disease-free survival (DFS) rates were 74.7%, 57.7%, and 32.6%, respectively. The monotherapy group demonstrated the best outcomes, whereas the salvage group had the poorest results. Age and T stage were independent predictors of OS, with local recurrence within 5 years linked to initial T stage in monotherapy (p = 0.057) and EBRT boost patients (p = 0.046). Chronic adverse events such as xerostomia, fibrosis, and dysesthesia were more prevalent in the salvage group compared to the other groups. CONCLUSIONS: HDR-IBT is an effective treatment for early-stage OTSCC, yielding favorable survival rates and manageable acute and chronic side effects, particularly when used in low-risk patients for regional recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyTongue NeoplasmsCarcinoma, Squamous CellSquamous Cell Carcinoma of Head and NeckHumansMaleFemaleMiddle AgedAgedTertiary Care CentersRadiotherapy DosageTreatment OutcomeRetrospective StudiesAdultSalvage TherapyAged, 80 and overSurvival RateNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Adjuvant radiotherapyBrachytherapyCancer of tongueSquamous cell carcinoma

Autor:innen und Institutionen

  • Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center, Cancer Research Institute,…
  • Full Professor and Director of Residency Program, Department of Oral and Maxillofacial Surgery, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran; Department of Head and Neck Surgical Oncology and…
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Kazemian@tums.ac.ir.
  • Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Istituto di Radiologia, Rome, Italy.

Zitieren

APA

Aghili, M., Jafari, F., Kolahdouzan, K., Biglar, F., Yousefi, A., Nabavi, M., Jaberi, R., Garajei, A., Abdshah, A., Kazemian, A., & Tagliaferri, L. (2026). Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.09.009

Vancouver

Aghili M, Jafari F, Kolahdouzan K, Biglar F, Yousefi A, Nabavi M, et al. Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.09.009

BibTeX
@article{Aghili2026,
  author = {Aghili, Mahdi and Jafari, Fatemeh and Kolahdouzan, Kasra and Biglar, Fatemeh and Yousefi, Ava and Nabavi, Mansoureh and Jaberi, Ramin and Garajei, Ata and Abdshah, Alireza and Kazemian, Ali and Tagliaferri, Luca},
  title = {Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2025.09.009}
}
Kostenlos starten →